Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Proc Natl Acad Sci U S A ; 119(12): e2116870119, 2022 03 22.
Artículo en Inglés | MEDLINE | ID: mdl-35302889

RESUMEN

SignificanceRecent political events show that members of extreme political groups support partisan violence, and survey evidence supposedly shows widespread public support. We show, however, that, after accounting for survey-based measurement error, support for partisan violence is far more limited. Prior estimates overstate support for political violence because of random responding by disengaged respondents and because of a reliance on hypothetical questions about violence in general instead of questions on specific acts of political violence. These same issues also cause the magnitude of the relationship between previously identified correlates and partisan violence to be overstated. As policy makers consider interventions designed to dampen support for violence, our results provide critical information about the magnitude of the problem.


Asunto(s)
Política , Violencia , Encuestas y Cuestionarios , Estados Unidos
3.
Am J Pol Sci ; 56(1): 98-114, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22400144

RESUMEN

Public agencies have discretion on the time domain, and politicians deploy numerous policy instruments to constrain it. Yet little is known about how administrative procedures that affect timing also affect the quality of agency decisions. We examine whether administrative deadlines shape decision timing and the observed quality of decisions. Using a unique and rich dataset of FDA drug approvals that allows us to examine decision timing and quality, we find that this administrative tool induces a piling of decisions before deadlines, and that these "just-before-deadline" approvals are linked with higher rates of postmarket safety problems (market withdrawals, severe safety warnings, safety alerts). Examination of data from FDA advisory committees suggests that the deadlines may impede quality by impairing late-stage deliberation and agency risk communication. Our results both support and challenge reigning theories about administrative procedures, suggesting they embody expected control-expertise trade-offs, but may also create unanticipated constituency losses.


Asunto(s)
Toma de Decisiones , Aprobación de Drogas , Vigilancia de Productos Comercializados , Salud Pública , United States Food and Drug Administration , Aprobación de Drogas/economía , Aprobación de Drogas/historia , Aprobación de Drogas/legislación & jurisprudencia , Industria Farmacéutica/economía , Industria Farmacéutica/educación , Industria Farmacéutica/historia , Industria Farmacéutica/legislación & jurisprudencia , Historia del Siglo XX , Historia del Siglo XXI , Organización y Administración/economía , Vigilancia de Productos Comercializados/economía , Salud Pública/economía , Salud Pública/educación , Salud Pública/historia , Salud Pública/legislación & jurisprudencia , Estados Unidos/etnología , United States Food and Drug Administration/economía , United States Food and Drug Administration/historia , United States Food and Drug Administration/legislación & jurisprudencia
4.
Lancet ; 373(9673): 1447-54, 2009 Apr 25.
Artículo en Inglés | MEDLINE | ID: mdl-19359034

RESUMEN

BACKGROUND: We assessed aspects of Seguro Popular, a programme aimed to deliver health insurance, regular and preventive medical care, medicines, and health facilities to 50 million uninsured Mexicans. METHODS: We randomly assigned treatment within 74 matched pairs of health clusters-ie, health facility catchment areas-representing 118 569 households in seven Mexican states, and measured outcomes in a 2005 baseline survey (August, 2005, to September, 2005) and follow-up survey 10 months later (July, 2006, to August, 2006) in 50 pairs (n=32 515). The treatment consisted of encouragement to enrol in a health-insurance programme and upgraded medical facilities. Participant states also received funds to improve health facilities and to provide medications for services in treated clusters. We estimated intention to treat and complier average causal effects non-parametrically. FINDINGS: Intention-to-treat estimates indicated a 23% reduction from baseline in catastrophic expenditures (1.9% points; 95% CI 0.14-3.66). The effect in poor households was 3.0% points (0.46-5.54) and in experimental compliers was 6.5% points (1.65-11.28), 30% and 59% reductions, respectively. The intention-to-treat effect on health spending in poor households was 426 pesos (39-812), and the complier average causal effect was 915 pesos (147-1684). Contrary to expectations and previous observational research, we found no effects on medication spending, health outcomes, or utilisation. INTERPRETATION: Programme resources reached the poor. However, the programme did not show some other effects, possibly due to the short duration of treatment (10 months). Although Seguro Popular seems to be successful at this early stage, further experiments and follow-up studies, with longer assessment periods, are needed to ascertain the long-term effects of the programme.


Asunto(s)
Política de Salud , Seguro de Salud , Programas Nacionales de Salud , Cobertura Universal del Seguro de Salud , Adulto , Niño , Preescolar , Análisis por Conglomerados , Femenino , Encuestas de Atención de la Salud , Gastos en Salud/estadística & datos numéricos , Humanos , Lactante , Masculino , México , Evaluación de Programas y Proyectos de Salud , Factores Socioeconómicos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA